期刊文献+

体外Rituximab增敏吉西他滨/长春瑞宾细胞毒作用的实验研究

Rituximab-mediated Sensitization of B-NHL Cell Lines to Apoptosis Induced by Gemcitabine and Navelbine In Vitro
下载PDF
导出
摘要 本研究探讨抗CD20单抗利妥昔(Rituximab,RTX)对Gemcitabine和Navelbine的化疗增敏作用及其可能的作用机制。体外培养Daudi、Ramos、Namalwa和Raji细胞,采用XTT法测定细胞增殖抑制率,计算出各自的IC50;比较Gemcitabine或Navelbine单药及Gemcitabine或Navelbine分别与RTX两药协同作用的IC50;用Western blot测定Daudi、Ramos、Raji和Namlwa细胞经RTX20μg/ml作用24小时后抗凋亡蛋白BCL-2的表达情况。结果表明:单药抗CD20单克隆抗体对4株细胞无明显诱导凋亡作用,抑制率在3%-10%之间波动。RTX可使Gemcitabine或Navelbine对Daudi、Namalwa和Raji细胞株的细胞毒作用有明显增强;在Namalwa和Raji细胞株经RTX作用24小时后,BCL-2蛋白表达下调。结论:RTX对新一代细胞毒药物Gemcitabine或Navelbine有明显的细胞毒增敏作用。Namalwa和Raji细胞株经RTX作用24小时后BCL-2表达下调,这可能是RTX增敏细胞毒药物的机制之一。 This study was purposed to explore the Rituximab (RTX)-mediated sensitization of B-NHL cell lines to apoptosis induced by Gemcitabine or Navelbine and its possible mechanism. The inhibitory rate of B-NHL cell proliferation was detected by XTT method, the IC50 from Gemcitabine or Navelbine and combination of Gemcitabine or Navelbine with RTX was compared. The expression level of antiapoptotic protein BCL-2 in Daudi, Ramos, Raji and Namalwa cells treated with RTX of 20 μg/ml for 24 hours was detected by Western blot. The results showed that the RTX as a single agent could weakly induce the apoptosis of Daudi, Namalwa, Raft and Ramos lymphoma cell lines, the inhibiting rate of cell proliferation ranged from 3% to 10% ; RTX could sensitize significantly the cytotoxity of Gemcitabine or Navelbine in Daudi, Namalwa and Raji cell lines; The expression of BCL-2 in Raji and Namalwa cell lines treated with RTX of 20 μg/ml for 24 hours was down-regulated. It is concluded that RTX can sensitize the cytotoxicity of Gemcitabine or Navelbine to the human lymphoma cell lines which displayed the synergistic effect on Daudi, Namalwa and Raji cell lines. The BCL-2 expression level in Raji and Namalwa cell lines treated by RTX is down-regulated which may be one of the mechanisms sensitizing the cytotoxicity of Gemcitabine or Navelbine.
出处 《中国实验血液学杂志》 CAS CSCD 2010年第4期873-876,共4页 Journal of Experimental Hematology
基金 广东省自然科学基金重点项目资助(基金号:05200178)
关键词 抗CD20单抗 B-淋巴瘤细胞株 增敏 Gemcitabine NAVELBINE Rituximab B-NHL cell line sensitization Gemcitabine Navelbine
  • 相关文献

参考文献11

  • 1Maloney DG, Grillo-Lopez A J, White CA, et al. IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin 's lymphoma. Blood, 1997 ; 90 ( 6 ) : 2188 -2195.
  • 2Feugier P, Van Hoof A, Sebban C,et al. Long-term results of the RCHOP study in the treatment of elderly patients with diffuse large B- cell lymphoma: a study by the Groupe dEtude des Lymphomes de l' Adulte. J Clin Oncol, 2005 ;23 ( 18 ) :4117 - 4126.
  • 3Shan D, Ledbetter JA, Press OW. Apoptosis of malignant human B cells by ligation of CD20 with monoclonal antibodies. Blood, 1998 ; 91 (5) :1644 - 1652.
  • 4Monfardini S, Aversa SM, Zoli V, et al. Vinorelbine and prednisone in frail elderly patients with intermediate-high grade non-Hodgkin's lymphomas. Ann Oncol, 2005 ; 16 ( 8 ) : 1352 - 1358.
  • 5Rodriguez J, Gutierrez A, Palaeios A, et al. Rituximab, gemcitabine and oxaliplatin: an effective regimen in patients with refractory and relapsing mantle cell lymphoma. Leuk Lymphoma, 2007; 48 (11) :2172 -2178.
  • 6Pasricha SR, Grigg A, Catalano J ,et al. A multicenter phase 2 study of risk-adjusted salvage chemotherapy incorporating vinorelbine and gemcitabine for relapsed and refractory lymphoma. Cancer, 2008; 113(11) :3192 -3198.
  • 7Ghetie MA, Bright H, Vitetta ES. Homodimers but not monomers of Rituxan (chimeric anti-CD20) induce apoptosis in human B-lymphoma cells and synergize with a chemotherapeutic agent and an immunotoxin. Blood, 2001 ;97(5) :1392 - 1398.
  • 8Cardarelli PM, Quinn M, Buckman D, et al. Binding to CD20 by anti-B1 antibody or F(ab') (2) is sufficient for induction of apoptosis in B-cell lines. Cancer Immunol Immunother, 2002 ;51 ( 1 ) : 15 -24.
  • 9Alas S, Ng CP, Bonavida B. Rituximab modifies the cisplatin-mitochondrial signaling pathway, resulting in apoptosis in cisplatin-resistant non-Hodgkin's lymphoma. Clin Cancer Res, 2002 ;8 (3) :836 - 845.
  • 10Vega MI, Huerta-Yepaz S, Garban H, et al. Rituximab inhibits p38 MAPK activity in 2F7 B NHL and decreases IL-10 transcription: pivotal role of p38 MAPK in drμg resistance. Oncogene, 2004;23 (20) :3530-3540.

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部